gms | German Medical Science

57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie (DGNN)

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie

12. - 15.09.2012, Erlangen

Banner: 57. Jahrestagung der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie

Intraoperative Alanin and histopathology are unable to demonstrate a recurrent glioblastoma, positively identified by FET PET-CT

Meeting Abstract

  • presenting/speaker Dieter Woischneck - Klinikum Landshut, Neurosurgery, Landshut, Germany
  • Willibald Permanetter - Klinikum Landshut, Pathology, Landshut, Germany
  • Wolfgang Feiden - Klinikum des Saarlandes, Neuropathology, Bad Homburg, Germany
  • Norbert Blumstein - Klinikum Landshut, Nuclear medicine, Landshut, Germany

Deutsche Gesellschaft für Neuropathologie und Neuroanatomie. 57th Annual Meeting of the German Society for Neuropathology and Neuroanatomy (DGNN). Erlangen, 12.-15.09.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. Doc12dgnnPP3.32

doi: 10.3205/12dgnn076, urn:nbn:de:0183-12dgnn0761

Veröffentlicht: 11. September 2012

© 2012 Woischneck et al.
Dieser Artikel ist ein Open Access-Artikel und steht unter den Creative Commons Lizenzbedingungen (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.de). Er darf vervielfältigt, verbreitet und öffentlich zugänglich gemacht werden, vorausgesetzt dass Autor und Quelle genannt werden.


Gliederung

Text

Questions: We report a fatal case of recurrent glioblastoma, in which neither intraoperative Alanin nor histopathology were able to demonstrate tumor growth. PET-CT was positive. Can operation be based on PET-CT findings alone ?

Case report: A 44 year old woman was treated for a glioblastoma of the right temporal lobe two years ago by operation and radiochemotherapy. Actually, a rapid neurological detoriation let to MRI-follow up, which revealed a tumor relapse of 70 cm3 . FET PET-CT visualized a clear uptake in 80% of the tumor volume. During the second operation, the tumor showed no alanin uptake. Due to postoperative, early MRI, 90% of the process had been removed. Histopathological examination did not confirm tumor growth, biochemical analysis of the spicemen was negative for gliobastoma specific markers . The patient improved for another 4 month and died with anew tumor progress due to MRI.

Conclusions: FET PET-CT was a highly specific modality for detecting recurrence in the glioblastoma reported and was effectively able to exclude post therapy changes. It was superior to histopathology, which has an impact on the indications for stereotactic procedures and intraoperativeinstantaneoussections. We propose a multicentre approach to collelct data systematically in order to compare the predictor qualities of PET-CT and histopathology.